Tiziana Life Sciences Ltd TLSA:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/15/24 EDT
0.60quote price arrow down-0.0317 (-4.9921%)
Volume
4,268
Close
0.635UNCH (UNCH)
Volume
179,105
52 week range
0.41 - 1.27
Loading...
  • Open0.60
  • Day High0.6355
  • Day Low0.5702
  • Prev Close0.635
  • 52 Week High1.27
  • 52 Week High Date06/05/23
  • 52 Week Low0.41
  • 52 Week Low Date04/15/24

Key Stats

  • Market Cap64.943M
  • Shares Out102.27M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.33
  • YTD % Change13.39

KEY STATS

  • Open0.60
  • Day High0.6355
  • Day Low0.5702
  • Prev Close0.635
  • 52 Week High1.27
  • 52 Week High Date06/05/23
  • 52 Week Low0.41
  • 52 Week Low Date04/15/24
  • Market Cap64.943M
  • Shares Out102.27M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.33
  • YTD % Change13.39

RATIOS/PROFITABILITY

  • EPS (TTM)-0.15
  • P/E (TTM)-4.24
  • Fwd P/E (NTM)-8.47
  • EBITDA (TTM)-14.531M
  • ROE (TTM)-50.61%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)1.87%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Tiziana Life Sciences Ltd

 

Profile

MORE
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb)...
Gabriele Cerrone
Executive Chairman of the Board
Kunwar Shailubhai
Chief Executive Officer, Chief Scientific Officer, Executive Director
Address
3Rd Floor, 11-12 St. James's Square
London
SW1Y 4LB
United Kingdom